Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs-Reference-Cited by-同舟云学术

Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs

Published:2016-12-12 Issue:2 Volume:17 Page:143-155
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Brückl Wolfgang¹,Tufman Amanda²,Huber Rudolf Maria²

Affiliation:

1. Department of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University, General Hospital Nuernberg, Nuremberg, Germany

2. Division of Respiratory Medicine and Thoracic Oncology, Department of Internal Medicine V, Thoracic Oncology Centre Munich, Ludwig-Maximilians Universität München, Munich, Germany

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2017.1266265

Reference70 articles.

1. Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions

2. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

3. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

4. Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline

5. Role of ErbB Receptors in Cancer Cell Migration and Invasion

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Osimertinib Induces the Opposite Effect of Proliferation and Migration in the Drug Resistance of EGFR-T790M Non-small Cell Lung Cancer Cells;Anti-Cancer Agents in Medicinal Chemistry;2023-07

2. A case of multiple primary lung adenocarcinoma with a CD74‐NRG1 fusion protein and HER2 mutation benefit from combined target therapy;Thoracic Cancer;2022-09-12

3. Chemotherapeutic Protocols for the Treatment of Lung Cancer;Chemotherapy Protocols and Infusion Sequence;2022

4. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers;Bioorganic Chemistry;2021-11

5. Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades;Pharmaceuticals;2021-07-22